[Oral Kaposi's sarcoma: role of radiotherapy].
Conill
C
C
Verger
E
E
Ferrer
F
F
Ferré
J
J
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use; D005500:Follow-Up Studies; D005887:Gingival Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D006679:HIV Seropositivity / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000532:radiotherapy*; D010157:Palatal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011739:Pyrimethamine / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000209:etiology / Q000532:radiotherapy*; D013411:Sulfadiazine / Q000627:therapeutic use; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D013411:Sulfadiazine; D014750:Vincristine; D014747:Vinblastine; D003907:Dexamethasone; D011739:Pyrimethamine
Sarcoma de Kaposi oral: papel de la radioterapia.